Abstract:4-anilinoquinazoline-based derivatives represent an attractive scaffold for small molecular EGFR-TKIs in the field of medicinal chemistry. A series of novel heterocyclic substituted derivatives have been designed, synthesized and evaluated their antitumor bioactivities as potential EGFR-TKIs. Most of the new compounds exhibited certain efficient inhibition potency for proliferation of a panel of five human cancer cells with IC50 values at the low micromolar level, and some of them possessed good broad-spectrum inhibition activities, compared to Gefitinib. Especially, the IC50 values of compound 21 against HepG2, A549, MCF-7, DU145 and SH-SY5Y cells were 4.61, 9.50, 9.80, 6.79 and 7.77 μM, respectively, which were much lower than those of Gefitinb. Furthermore, the highlighting compound 21 demonstrated excellent inhibition activity against EGFR-TK with the IC50 value of 3.62 nM, similar to that of Gefitinib(2.21 nM). The results of LDH release assay proved that compound 21 was anti-proliferative rather than cytotoxicity on HepG2 cells. Compound 21 were able to cause HepG2 cells to block in S phase and induce cell death mainly by apoptosis through a mitochondrial dependent pathway. Moreover, the assessment of MMP, the determination of intracellular free Ca2+ concentration, the production of ROS, and the effects on the activity of caspase-3 in a dose-dependent manner demonstrated that compound 21 induced cell apoptosis in HepG2 cells through the Ca2+/ROS-mediated mitochondria/caspase-dependent apoptosis pathway largely. These preliminary results evidenced that compound 21 could be a potential antitumor agent deserving further study.

Combination of 4-Anilinoquinazoline and Rhodanine As Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

Discovery of Novel 4-Anilinoquinazoline Derivatives As Potent Inhibitors of Epidermal Growth Factor Receptor with Antitumor Activity.

The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, Synthesis and Biological Evaluation of Novel 4-Anilinoquinazolines with C-6 Urea-Linked Side Chains As Inhibitors of the Epidermal Growth Factor Receptor.

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis, Characterization, Screening And Docking Analysis Of 4-Anilinoquinazoline Derivatives As Tyrosine Kinase Inhibitors

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors

Design and Synthesis of 4,6-Substituted-(diaphenylamino)quinazolines As Potent Egfr Inhibitors with Antitumor Activity

Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.

Development of a Series of Novel 4-Anlinoquinazoline Derivatives Possessing Quinazoline Skeleton: Design, Synthesis, EGFR Kinase Inhibitory Efficacy, and Evaluation of Anticancer Activities in Vitro.

Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.

Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors

Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors

Optimization of Substituted 6-Salicyl-4-anilinoquinazoline Derivatives As Dual Egfr/Her2 Tyrosine Kinase Inhibitors

Four-membered Heterocycles-Containing 4-Anilino-quinazoline Derivatives As Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors

Design, Synthesis and Biological Evaluation of 6-(Nitroimidazole-1h-alkyloxyl)-4-anilinoquinazolines As Efficient EGFR Inhibitors Exerting Cytotoxic Effects Both under Normoxia and Hypoxia.

Research Progress on Quinazoline Derivatives with Epidermal Growth Factor Receptor Inhibiting Bioactivity

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers